Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. on March 27, 2020. The filing reports the entry into a material definitive agreement to establish an At-The-Market (ATM) equity offering program.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed is the authorization to raise up to $35.0 million in aggregate gross proceeds through the sale of common stock.
Material Changes
On March 27, 2020, the Company entered into a Sales Agreement with Stifel, Nicolaus & Company, Incorporated. This agreement allows the Company to sell shares of its common stock through Stifel as agent in "at-the-market" offerings on the Nasdaq Capital Market or in negotiated transactions.
Guidance, Outlook, and Terms
- Offering Structure: Sales will be made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-229140).
- Compensation: The Company agreed to pay Stifel a commission of up to 3.0% of the aggregate gross proceeds from shares sold.
- Termination: The agreement terminates upon the sale of all authorized shares or earlier termination by either party.
- Expenses: The Company will reimburse Stifel for certain specified expenses related to the agreement.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of selling up to $35.0 million in equity.
- Review the effective shelf registration statement (File No. 333-229140) for existing outstanding shares and restrictions.
- Monitor future filings to track the actual volume of shares sold and proceeds generated under this ATM program.
- Assess the Company's cash runway and capital needs given the decision to utilize an ATM facility.